Navigation Links
Recurrence of aggressive uterine cancer reduced by new form of therapy

The incidence of uterine papillary serous carcinoma (UPSC) has increased since it was first identified in 1981. The condition was initially regarded as easy to treat until about 1990 when a number of persons were diagnosed with the // aggressive cancer. It has remained a significant problem since then.

UPSC is found in higher rates in African American women than in white women. The disease looks like ovarian cancer and spreads just as rapidly, restricting the choice of treatment to only chemotherapy.

A state-of-the-art treatment program now developed at Yale School of Medicine has been found to increase survival from the aggressive uterine papillary serous carcinoma (UPSC) sparing the need for additional therapy in some patients.

According to the study, it has been that a combination of platinum-based chemotherapy and vaginal radiation to be the most effective treatment for the disease. This has infact led to the establishment of a standard of care being established for this type of uterine cancer.

Moreover, it can also be used to evaluate the need for additional treatment following surgery and hence determine the prognosis. The survival rates of women have considerably increased with reduction in the recurrence rates.

The study was conducted on a group of 74 patients with UPSC who underwent complete surgical staging, or hysterectomy with removal of lymph nodes and fat pads. Cancer recurred in 43 percent of early stage patients who did not receive chemotherapy, while in the 20 percent of patients who received platinum-based chemotherapy there were no recurrences. About 14 patients were spared additional radiation treatment.
'"/>




Page: 1

Related medicine news :

1. Lowering Risk of Breast Cancer Recurrence
2. HRT Found To Increase Recurrence of Breast Cancer
3. The Link Between HRT And Recurrence of Breast Cancer
4. Tumour marker for detecting early Recurrence of Thyroid cancer may be soon available
5. Predicting Breast Cancer Recurrence By Understanding Gene Signature
6. Combination Therapy To Avoid Prostate Cancer Recurrence
7. Cervical Cancer Recurrence Risk Even After Removal Of Pre-Cancerous Cells
8. Drugs Are Effective In Treating Depression and Preventing Recurrence
9. PET-CT Scores High On Precision for Diagnosing Ovarian Cancer Recurrence
10. Experts Warn of Bird Flu Recurrence in Maharashtra
11. Petition On Recurrence Of Dengue And Malaria In Kolkata
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills ... specialty vendors and unique items from across the nation, this holiday-themed event will raise ... offered by the VNA. The boutique will be open Saturday, November 4 (10:00 ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... CAESAREA, Israel and NEW YORK , Sept. ... company with mobile health and big data solutions, today announced that its ... today. Please check your local TV listings for when The Dr. Oz ... ... ninth season this month. ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: